Astellas Pharma (OTCMKTS:ALPMY) Sees Strong Trading Volume – Still a Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw an uptick in trading volume on Monday . Approximately 133,468 shares were traded during trading, a decline of 15% from the previous session’s volume of 157,048 shares.The stock last traded at $15.07 and had previously closed at $15.18.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Astellas Pharma Price Performance

The company has a quick ratio of 0.93, a current ratio of 1.20 and a debt-to-equity ratio of 0.16. The stock’s 50-day moving average price is $14.36 and its 200 day moving average price is $14.53. The firm has a market capitalization of $27.38 billion, a price-to-earnings ratio of 11.51 and a beta of 0.08.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions.

The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes.